2024 Report: The State of Diversity and Equity in Clinical Trials

The road to improving equitable access to healthcare starts here.

From the latest FDA guidelines to generative AI, H1’s newest report examines the state of diversity and equity in clinical trials to identify opportunities for pharma organizations to incorporate the latest developments, market trends, and strategic insights that are critical for enhancing diversity in clinical trials.

This informative report will prepare you to:

• Meet FDA regulations on Diversity Action Plans for trial sponsors.
• Ensure diverse representation by using Generative AI to identify sites, PIs, and patients.
• Set reasonable recruitment benchmarks within each indication based on patient burden.

It’s time for pharmaceutical organizations to ensure research findings are applicable to the entire population to help foster improved health outcomes for all demographic groups.

Download the full report today to discover more about the state of diversity and equity in clinical trials.